Background We sought to determine the etiologies, diagnostic testing, and management of a retrospective cohort of patients with camptocormia evaluated at a single center.
techniques include goniometric analysis and Cobb angle. 15 Despite growing evidence, the most recent version of the ICD-10 puts camptocormia in the same category as conversion disorder.
In this study, we evaluate a large cohort of patients with camptocormia in a tertiary medical center, and present an updated range of etiologies, diagnostic workup, and management.
Methods
We retrospectively identified all patients with a diagnosis of camptocormia at Mayo Clinic Rochester between 2000 and 2014. Search keywords were "camptocormia" and "bent spine syndrome." We included patients age 18 or older, who had ≥45°of forward spinal flexion. Patients with minimally stooped posture, lateral flexion, congenital spine deformity, fixed spinal flexion deformity that did not resolve in the supine position, or lack of a definitive diagnosis of camptocormia were excluded. Degree of camptocormia was not measured objectively in all cases and was based on descriptive documentation by the physician. The initial search yielded 412 patients. Of these, 136 patients were excluded, leaving 276 patients included in the final cohort. All patients were evaluated by a spine, orthopedic, neuromuscular, or movement disorders specialist at our institution.
Demographic and clinical data were extracted. Recorded variables included age, sex, etiology, or condition associated with camptocormia as determined by the evaluating physician, diagnostic studies performed (needle EMG, brain and spine MRI, multichannel surface EMG, muscle biopsy), and treatment modalities. Diagnosis was assigned based on impression of the evaluating physician in conjunction with the available diagnostic data. Elevated creatine kinase (CK) was defined as any value above the set reference normal range for the Mayo Medical Laboratories' photometric assay: 52-336 u/L for adult men and 38-176 u/L for adult women. Data were recorded in a secure Redcap database. Descriptive statistics were calculated using JMP software.
Standard protocol approvals, registration, and patient consent This study was approved by the Mayo Clinic internal review board/ethics committee. Written informed consent was waived due to the retrospective nature of the study.
Data availability
All data associated with this study are reported in this article. No data will be deposited.
Results
Of 276 patients with camptocormia, 58% were male, with a mean age at presentation of 68.6 (±12.7) years. Their demographic, clinical, and diagnostic workup features are summarized in table 1. Table 2 lists the etiologies of camptocormia in these 276 patients. Certain conditions were considered causative, such as myopathy and dystonia, whereas others were thought to be associated with camptocormia by the evaluating physicians. These are discussed below.
Etiologies

CNS and neurodegenerative disorders
Camptocormia was associated with a number of neurodegenerative disorders. The most common was idiopathic Parkinson disease (PD) in 22.5% patients, followed by truncal dystonia (7.3%), multiple system atrophy (5.8%), dementia with Lewy bodies (3.3%), frontotemporal lobar degeneration (1.1%), progressive supranuclear palsy, and Alzheimer disease (0.7% each). Dystonia may occur in isolation without prominent degeneration or as part of a neurodegenerative process. These patients were diagnosed clinically by a movement disorders or behavioral neurology specialist at our center. PD diagnosis was based on clinical features, levodopa responsiveness, and absence of red flags for atypical parkinsonism, and atypical parkinsonism if patients did not meet these criteria.
Neuromuscular disorders
These patients were younger than the other subgroups, with a mean age at diagnosis of 50 years. The most common etiology was idiopathic axial myopathy in 14.1% (n = 39). These cases had an isolated or predominantly paraspinal myopathic process, with myopathic features on muscle biopsy or paraspinal EMG. MRI of the spine in revealed paraspinal muscle atrophy and fatty infiltration of varying degrees. Degenerative joint disease in these cases was mild. A muscle biopsy was performed in 22 of these 39 patients at the following locations: thoracic paraspinal (n = 4), gluteus maximus (n = 5), splenius capitis (n = 3), trapezius (n = 3), quadriceps (n = 3), deltoid (n = 2), cervical paraspinal (n = 1), and vastus medialis (n = 1). The findings were those of nonspecific myopathy, such as muscle fiber splitting, fatty infiltration, and atrophy. Other myopathies and muscular dystrophies associated with camptocormia often presented
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with more widespread muscle weakness. These included facioscapulohumeral muscular dystrophy (2.5%), inflammatory myopathies (2.1%), inclusion body myositis (1.4%), mitochondrial myopathy (1.1%), myotonic dystrophy (1.1%), dysferlinopathy (0.7%), and rarely nemaline myopathy and central core myopathy, with 1 case of each (0.3%). Amyotrophic lateral sclerosis was diagnosed in 9.4%, myasthenia gravis in 1.8%. Patients undergoing treatment of myasthenia gravis and inflammatory myopathy had partial improvement. All patients were seen by a neuromuscular specialist at our center.
Musculoskeletal disorders
Camptocormia was attributed to severe degenerative joint disease in 13.0% (n = 36). These were distinguished from cases of axial myopathy based on predominance of severe degenerative joint disease and spondylosis in the cervical/ thoracic/lumbar spine. These patients had a predominance of neurogenic changes on EMG and denervation atrophy on muscle biopsy as shown in table 3. Most of these patients were evaluated by an orthopedic or spine specialist.
Immune-mediated disorders There were 7 cases (2.5%) where an autoimmune antibody was identified in the absence of other causes of camptocormia. None was associated with an underlying malignancy. GAD-65 antibody was elevated in 2 patients and the clinical phenotype was consistent with stiff-person syndrome. There was partial improvement of the camptocormia with benzodiazepines and immunotherapy. Two patients had voltage-gated potassium channel (VGKC) antibodies, which were not speciated into contactin associated protein-2 (Caspr-2) or leucine-rich glioma inactivated protein-1 (LGI-1). One patient had an elevated Ntype calcium channel antibody. Steroid therapy was trialed unsuccessfully in the cases with elevated VGKC antibody, raising suspicion that these antibodies may be unrelated to the clinical phenomenon.
Miscellaneous/rare Drug-induced causes were uncommon and included olanzapine 0.7%, levodopa-induced dystonia 0.7%, and steroid related myopathy 0.4%. Improvement was noted after discontinuation of the drug. Other infrequent causes are listed in Paraspinal muscle atrophy 7 (9.7)
Narrow spinal canal 1 (1.4) Syrinx 2 (2.7)
MRI lumbosacral spine 187 (67.8)
Degenerative joint pathology 145 (77.5) 
Other clinical features
An associated head drop was seen in 14.5%. This was most commonly seen in patients with axial myopathy (n = 10) or PD (n = 6). Less common causes were multiple system atrophy (n = 4), dystonia (n = 4), degenerative joint disease (n = 3), idiopathic axial myopathy (n = 3), amyotrophic lateral sclerosis (n = 2), myotonic dystrophy (n = 2), Alzheimer disease (n = 1), inflammatory myopathy (n = 1), inclusion body myositis (n = 1), myasthenia gravis (n = 1), facioscapulohumeral muscular dystrophy (n = 1), and Lewy body disease (n = 1). Twenty-two patients (7.9%) had a family history of camptocormia, only observed in patients with facioscapulohumeral muscular dystrophy, myotonic dystrophy, or idiopathic axial myopathy.
Diagnostic evaluation
All patients underwent supplementary testing in addition to clinical examination. The findings are summarized in table 1,  whereas table 3 compares findings between the most common subgroups.
Three-quarters of cases (n = 207) underwent EMG. Of these, 18.4% were normal, 47.3% revealed predominantly myopathic findings, 32% had predominantly neurogenic findings, and 2.4% patients had a neuromuscular transmission defect.
Of the 39 patients with axial myopathy, 36 had myopathic findings on EMG and 3 had neurogenic findings. Of 36 patients with degenerative joint disease, 32 underwent EMG, which showed predominantly neurogenic changes in 15, myopathic changes in 11, and 6 were normal.
A movement disorders laboratory study with multichannel surface EMG was performed for 9.1% of patients with suspected dystonia. One-third confirmed dystonia, half of the studies were normal, and the rest were inconclusive.
Muscle biopsy was performed in 61 patients with muscle weakness on examination. The biopsy site was selected based on affected muscle by EMG, and rarely by MRI. Biopsy sites included the following: thoracic paraspinals (n = 13), gluteus maximus (n = 9), biceps (n = 6), splenius capitis (n = 6), trapezius/vastus/quadriceps (n = 5 each), triceps (n = 4), deltoid (n = 3), pectoralis (n = 2), and 1 case each of gastrocnemius, cervical, and lumbar paraspinals. Of the 61 biopsies, 2 were normal. The other 59 were abnormal, and the most common findings included nondiagnostic myopathic features with fatty infiltration (n = 33), inflammatory findings (n = 7), mitochondrial myopathy (n = 3), and denervation atrophy (n = 16). Of the 7 patients with inflammatory findings, 6 were eventually diagnosed as inflammatory myopathy. Muscle biopsy was instrumental in diagnosis of a few cases of camptocormia due to central core myopathy, nemaline rod myopathy, and inflammatory myopathy. All causes identified to be associated with camptocormia in this cohort of 276 patients.
Mild CK elevation was found in 39 patients, 31 of whom had myopathic features on muscle biopsy but were not diagnostic of specific disease process. CK elevation was not independently diagnostic.
Neuroimaging included MRI of the brain, cervical, thoracic, and lumbar spine. MRI brain was performed in 49.6% and was normal for age in most cases. The most common findings on spine MRI are summarized in table 1. A syrinx noted in the cervicothoracic spinal cord in 2 patients was deemed to be asymptomatic.
Treatment
The most common causes of camptocormia, test findings, and treatment modalities are summarized in table 4.
Three-quarters of patients were treated with physical therapy, with limited benefit. Almost one-third (30.8%) of patients underwent a trial of levodopa therapy, for idiopathic PD (n = 48), multiple system atrophy (n = 10), Lewy body disease (n = 8), dystonia (n = 15), and other unclear diagnoses, which were eventually found to be non-levodoparesponsive pathologies, such as myopathy (n = 4). In almost 50% of cases associated with idiopathic PD, mild to moderate subjective improvement was documented. Anterior or posterior spinal fixation surgery was performed for 15 patients (5.4%), including degenerative joint disease (n = 7), PD (n = 5), and axial myopathy (n = 3). There was improvement in posture noted in all patients; however, long-term follow-up was limited.
Botulinum toxin was administered in 10 cases with presumed dystonia: 4 had PD, 5 had surface EMG proven dystonic camptocormia, and 1 was subsequently not found to have dystonia on surface EMG. Botulinum toxin produced partial benefit in 6 of the 10. Muscles injected included iliopsoas, rectus abdominis, and transverse abdominis.
Deep brain stimulation surgery was performed for camptocormia in 4 patients with PD. Two patients underwent bilateral globus pallidus interna implantation with no improvement, and 2 underwent bilateral subthalamic nucleus implantation, one of whom had mild benefit.
Patients with myasthenia gravis (n = 5) and inflammatory myopathies (n = 6) were administered steroids and immunosuppressants, with at least partial subjective improvement in almost all patients. However, an objective measure of improvement and the duration of the therapeutic response was poorly documented.
Follow-up at Mayo Clinic was available for 115 (41.7%) of the patients for a median of 8 months (interquartile range 6-12). However, due to incomplete documentation, assessment of response to treatment was limited.
Discussion
In this study, we describe a large cohort of camptocormia patients, and report several novel findings. An underlying etiology can be discovered in almost all cases of camptocormia; hence a thorough evaluation guided by history and examination is warranted. PD, axial myopathy, and spine degenerative joint disease were the most common etiologies underlying camptocormia. There is an opportunity of improving camptocormia when the underlying etiology identified is amenable to treatment. If not, treatment appears to be of limited efficacy.
A wide range of disease processes associated with camptocormia is reported in the literature. These include PD, 16, 17 myopathy and muscular dystrophy, [18] [19] [20] multiple system atrophy, 9 and other neurodegenerative disorders like Alzheimer disease and dementia with Lewy bodies. 11, 21 Relatively rare cases are associated with drug side effect, 22 radiation-induced myopathy, 23 tetanus, 24 and calpainopathy. 18 Our study replicated prior reports and identified several etiologies not previously reported: progressive supranuclear palsy, central core myopathy, dystonia-myoclonus syndrome, and postpolio syndrome. We found the most common causes of camptocormia to be idiopathic axial myopathy, PD, and degenerative spine disease. Other large case series in the literature examine the prevalence and causes of camptocormia in subspecialty neurology clinics where this presentation is mostly seen, i.e., movement disorders and neuromuscular clinics. A series of 63 cases (73% female) reported the most common etiology was paraspinal myopathy.
14 Of 52 patients presenting with camptocormia at the neuromuscular clinic at our institution, a specific diagnosis was reached in 54%, the most common causes being facioscapulohumeral muscular dystrophy and inclusion body myositis. 25 In another study of 275 patients with PD, 6.9% had camptocormia. This was associated with more severe disease, longer disease duration, dementia, and higher levodopa doses. 16 The pathophysiology of camptocormia in PD is not known, but speculated mechanisms include myopathy, extrapyramidal system dysfunction, or dystonia. 17 The wide range of possible etiologies make it essential for the investigating physician to carry out a thorough evaluation and objective measurement of forward flexion when possible.
It is important to distinguish degenerative joint disease (without fixed deformity) from isolated idiopathic axial PD, axial myopathy, and spine degenerative joint disease were the most common etiologies underlying camptocormia myopathy. In our cohort, patients were assigned the diagnosis of degenerative spine disease based on CT and MRI spine findings of severe osteoarthritis, and the opinion of the evaluating orthopedic or spine specialist. The EMG revealed primarily neurogenic changes; however, some cases had mixed findings of both neurogenic and myopathic features. Differences between the pattern of paraspinal muscle fiber degeneration seen in spinal osteoarthritis vs paraspinal myopathy have been reported previously. 6, 17 The exact pathogenesis is unknown, and potentially some degree of overlap exists between the 2 conditions. A careful evaluation and exclusion of other treatable pathologies is strongly recommended in these cases.
Diagnostic testing should be guided by history and examination, and a diagnostic algorithm is proposed in the figure. Commonly performed tests include MRI or CT imaging of the spine, needle EMG, and CK. Individualized tests include muscle biopsy, surface EMG, and specific serology for genetic and autoimmune myopathies. Spine imaging commonly reveals nonspecific muscle atrophy and fatty infiltration and may vary based on chronicity of camptocormia. 26 As shown by prior series, 14,25 our cohort confirms that CK elevation in these patients is usually mild and nondiagnostic. A specific diagnosis is most likely to be achieved where a targeted test is performed based on high clinical index of suspicion; for example, gene testing for facioscapulohumeral muscular dystrophy, muscle biopsy for inflammatory myopathy and myositis, serology for autoimmune myopathy, or surface EMG to confirm dystonia, which could lead to efficacious therapy. Treatment for camptocormia appeared ineffective in most cases. However, when therapy could be targeted to a specific treatable disease, a better response was seen.
There are cases of dystonia successfully treated with pallidal and subthalamic deep brain stimulation reported in the literature. Srivanitchapoom and Hallett 17 reviewed 56 cases of camptocormia in PD, 51 of which underwent subthalamic stimulation and 5 pallidal stimulation. Of these, 61% had improvement with stimulation. However, most cases have limited follow-up and modest improvement. Complete resolution of camptocormia, as described in case reports, 27, 28 was not replicated in our patients with PD with camptocormia. This variation may reflect complex pathophysiology and an unclear neural substrate underlying camptocormia, which most likely represents a heterogeneous condition. Spinal stimulation may provide short-lived benefit, 29 but was not performed in our cohort. Botulinum toxin can be efficacious in dystonic camptocormia. Prior reports have targeted the iliopsoas and external oblique muscles with some benefit. [30] [31] [32] Levodopa leads to unpredictable partial benefit in some patients with PD. The mechanism of this response is not well-understood and is particularly interesting in view of higher doses of levodopa being associated with camptocormia; albeit this may be a surrogate of more severe disease. 6 In our cohort, there was moderate response to immunotherapy in inflammatory myopathy and myasthenia gravis. The most commonly used methods of physical therapy and extension bracing have limited benefit in the short term and may serve to slow down paraspinal muscle deconditioning. 33 Lidocaine injections of the external oblique muscles of patients with PD were reportedly efficacious in a few cases, 34 but were not used in our patient population. Overall, response to treatment in camptocormia is partial at best, with higher likelihood of improvement where therapy can directly target the underlying etiology. Long-term follow-up along with objective measurement of camptocormia will increase our knowledge of this heterogeneous condition.
This study has several strengths. We describe the largest cohort of camptocormia patients evaluated at a single center, without limiting our selection to a subspecialty clinic; hence all causes of camptocormia were captured. The broad array of diagnostic and treatment options noted in this patient cohort allowed us to put forward a diagnostic and treatment algorithm. We highlight important clinical points to be considered when evaluating camptocormia and provide useful groundwork for future studies. A limitation was the lack of objective measurement of the degree of forward spinal flexion. This made it difficult to accurately capture severity of camptocormia and response to treatment. Since this was a retrospective study, diagnostic workup performed for each patient varied based on the evaluating physician. Diagnosis assigned was based on best physician judgement at the end of diagnostic workup, and due to the retrospective nature, some diagnoses may have evolved and changed over time. Being a tertiary referral center, several patients elected to follow-up locally after completion of diagnostic evaluation, hence data on response to treatment and long-term course of the condition were limited.
Camptocormia is a progressively disabling condition. Pathophysiology is diverse and incompletely understood. The underlying etiology should be sought in all cases, as it may lead to effective treatment in some patients. Objective documentation of the extent of camptocormia will help quantify deformity and response to treatment. We propose a diagnostic and treatment approach based on a large singlecenter cohort of camptocormia.
TAKE-HOME POINTS
Camptocormia is a 45°or greater forward flexion of the spine caused by a variety of neurologic and musculoskeletal disorders.
Thorough investigation should be guided by history and physical as a diagnosis can be made in most cases.
Treatment options are limited. Better prognosis may be expected when a treatable etiology is discovered.
Objective measurement of the extent of spinal flexion is important for diagnosing and assessing treatment response.
